Clinical Trial Update: Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab and ipilimumab for metastatic/recurrent major and minor salivary gland carcinomas; status/results are not clearly provided in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Salivary Gland Carcinoma
• Minor Salivary Gland Carcinoma
• Salivary Gland Carcinoma
• Stage Iva Major Salivary Gland Carcinoma
• Stage Ivb Major Salivary Gland Carcinoma
• Stage Ivc Major Salivary Gland Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Northwestern University | Conditions: Major Salivary Gland Carcinoma, Minor Salivary Gland Carcinoma | Phase 2 | Status: UNKNOWN | Results posted: 2024-01-18